MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

NASDAQHealthcareBiotechnology
最新数据
US$49.55
−US$3.86 · -7.23%
前收盘价
US$49.55
−US$3.86 · -7.23%
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
40
偏贵
情绪
55
多空交织
风险
39
中等风险
动量
81
强势上行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日内区间
当前US$49.55
52周区间
当前US$49.55
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 销货成本 | 24.8万 USD | — | — | — |
| 毛利 | −24.8万 USD | — | — | — |
| 研究与开发 | 7915.9万 USD | 5741.5万 USD | 2853.4万 USD | 2139.7万 USD |
| 销售、一般及管理费用 | 1889.6万 USD | 1077.9万 USD | 677.7万 USD | 376.4万 USD |
| 营业费用 | 9805.5万 USD | 6819.4万 USD | 3531.1万 USD | 2516.1万 USD |
| 利息收入 | 1108.4万 USD | 627.2万 USD | 274.8万 USD | 37.2万 USD |
| 利息支出 | — | — | — | 37.4万 USD |
| 折旧和摊销 | 24.8万 USD | 24.4万 USD | 15.7万 USD | 5.6万 USD |
| 营业利润 | −9805.5万 USD | −6819.4万 USD | −3531.1万 USD | −2516.1万 USD |
| 净利润 | −8697.1万 USD | −6192.2万 USD | −3256.3万 USD | −2613.5万 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$97.67
上涨空间 97.11%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4757.78万0.00%6893亿 USD0.03%US$340.02-3.52%
iShares Russell 2000 ETFIWM4148.65万0.06%715.37亿 USD0.19%US$256.61-2.88%
Vanguard Extended Market ETFVXF1897.71万0.02%302亿 USD0.05%US$211.44-3.21%
iShares Russell 2000 Growth ETFIWO1559.8万0.12%127.32亿 USD0.24%US$320.43-3.57%
iShares Biotechnology ETFIBB1171.31万0.11%105.27亿 USD0.44%US$199.54-2.05%
Vanguard Russell 2000 ETFVTWO1019.57万0.06%168亿 USD0.06%US$103.76-2.76%
State Street SPDR S&P Pharmaceuticals ETFXPH914.21万1.82%5.01亿 USD0.35%US$62.15-2.00%
Schwab U.S. Small-Cap ETFSCHA829.45万0.04%204.47亿 USD0.03%US$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWO
State Street SPDR S&P Pharmaceuticals ETFXPH
Schwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。